Dr. Reddy's Laboratories (NVO) will launch its off-patent version of Novo Nordisk’s (NVO) blockbuster GLP-1 therapy Ozempic in Canada within the “next few days,” becoming the first to sell a generic ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The day has ...

The most significant addition to the Java language since Sun Microsystems rewrote the collections API for Java 5 is the introduction of Java records. Java records address two significant pain points ...

The audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results. Global ...

Apotex Inc., Canada’s largest drug maker, has won Health Canada approval to sell a generic form of the blockbuster Ozempic. The Toronto-based company is the second manufacturer to get an approval, ...

Java is an object-oriented programming language. To create objects and meaningfully initialize them, a developer must use a Java constructor. Constructors are a critical part of software development ...

The audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results. Health Canada ‌ ...

Health Canada has approved the first generic version of brand-name Ozempic. The department says Canada is the first G7 country to authorize generic semaglutide. The injectable medication is ...

Indian pharmaceutical company Dr. Reddy’s Laboratories Ltd. has become the first drug maker approved by Health Canada to sell a generic version of the blockbuster drug Ozempic. The authorization comes ...

The FDA approved the first generics of dapagliflozin (Farxiga) tablets for adults with type 2 diabetes, the agency announced on Tuesday. Generics of the SGLT2 inhibitor are indicated for glycemic ...

Generic dapagliflozin is indicated to lower heart failure hospitalization risk in type 2 diabetes with established cardiovascular disease or multiple risk factors, and to improve glycemic control ...